MIM Fertility, a leader in AI solutions for fertility specialists, and Esco Lifesciences, a top life science company, are excited to announce a strategic collaboration.

Esco Medical, a business unit of Esco Lifesciences Group, leads in delivering comprehensive workflow solutions for assisted reproduction technologies (ART) to IVF clinics, laboratories, and research centers worldwide. By focusing on streamlining processes and optimizing outcomes, Esco Medical offers an integrated portfolio, including high-quality Time-Lapse Incubators, IVF Workstations, and witnessing and traceability system designed in Denmark and manufactured in
Europe.

This partnership aims to enhance fertility treatments and improve patient outcomes by integrating advanced AI technology with cutting-edge laboratory equipment.

The key Objective for this collaboration is product integration.

 

EMBRYOAID®, an AI-powered embryo assessment tool, will seamlessly integrate with MIRI® Time-Lapse Incubators by Esco, allowing users to benefit from the AI-powered embryo assessment by MIM Fertility.

The companies will also develop and execute marketing campaigns to promote the integrated solutions, showcasing the combined strengths and innovations of both companies.

Pictured at ESHRE 2024 in Amsterdam, at the MIM Fertility booth are: Domantas Armonavičius (Product Manager), Ricky Lindgaard Nielsen (Head of R&D), and Tenzin Gocha (Director, Corporate Development and M&A) – representatives of Esco Lifesciences.

They are joined by Joanna Kusmierczyk-Kubiak (Head of Business Development) and Ula Sankowska (CEO) – representatives of  MIM Fertility.

.

“We are thrilled to partner with Esco Lifesciences,”

said Ula Sankowska, CEO of MIM Fertility.

“This collaboration sets a new standard in fertility treatment by combining AI-powered EMBRYOAID® with Esco’s MIRI® Time-Lapse Incubators.”

.

 Like what you read? Sign up for our newsletter for more insights, resources, and discussions.

Contribute with a commentary, research, or an idea.